Clinical Study

Ea6174- A Phase III Randomized Trial Of Comparing Adjuvant Mk-3475 (Pembrolizumab) To Standard Of Care Observation In Completely Resected Merkel Cell Carcinoma

Posted Date: Aug 8, 2019

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

The goal of this study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) as co-primary endpoints across the two arms.

Criteria:

To Be Eligible: 18 Years Or Older, Nonpregnant/Breastfeeding, Diagnosed With Merkel Cell Carcinoma, Must Not Have Recent Life Threatening Illness Or Cancer Within 2 Years.

Keywords:

Skin Cancer, Merkel Cell

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.